| I-01 Nurul Azrin Abd Rahman A population pharmacokinetic/pharmacodynamic (PK/PD) model of the investigational antimalarial drug Artefenomel in a Plasmodium vivax Volunteer-Infection Study Wednesday 09:50-11:15 |
| I-02 Mahmoud Abdelwahab Clofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis Wednesday 09:50-11:15 |
| I-06 Ahmed Aliyu Abulfathi External validation of a para-aminosalicylic acid population pharmacokinetics model using the ncappc R package Wednesday 09:50-11:15 |
| I-11 Marie Alexandre Modeling viral rebound in HIV therapeutic vaccine studies Wednesday 09:50-11:15 |
| I-15 Vincent Aranzana-Climent Use of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii Wednesday 09:50-11:15 |
| I-23 Rami Ayoun Alsoud Simultaneous Assessment of Time-to-positivity and Colony-forming Unit in tuberculosis patients under high-dose rifampicin therapy Wednesday 09:50-11:15 |
| I-56 David Busse Analysis of target-site distribution of meropenem in morbidly obese and non-obese patients using nonlinear mixed-effects modelling Wednesday 09:50-11:15 |
| I-58 Unai Caballero Pharmacodynamic modelling to evaluate the in vitro activity of amphotericin B against Candida auris Wednesday 09:50-11:15 |
| I-70 Alexia Chauzy Semi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria Wednesday 09:50-11:15 |
| I-72 Lu Chen Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis Wednesday 09:50-11:15 |
| I-73 Maxwell Chirehwa Population pharmacokinetics of cycloserine dosed as terizidone in drug-resistant tuberculosis patients Wednesday 09:50-11:15 |
| I-75 Palang Chotsiri Mechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity Wednesday 09:50-11:15 |
| I-78 Perrine Courlet Influence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV. Wednesday 09:50-11:15 |
| II-10 Donghwan Lee Effect of Pharmacokinetic Model Misspecification on Antibiotic Probability of Target Attainment Predicted by Monte Carlo Simulation Wednesday 15:10-16:40 |
| II-21 Feiyan Liu Modeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide Wednesday 15:10-16:40 |
| II-67 Taniya Paiboonvong Development of physiologically based pharmacokinetic model of sitafloxacin in plasma and epithelial lining fluid Wednesday 15:10-16:40 |
| II-68 Semra Palic Neopterin dynamics in pediatric patients after miltefosine treatment of visceral leishmaniasis Wednesday 15:10-16:40 |
| II-81 Mélanie Prague In Silico Clinical Trials for Evaluation of HIV Short-Cycle strategies Wednesday 15:10-16:40 |
| II-85 Chetan Rathi Model-Informed selection of doses and sample size for a Phase 2a POC study of GSK3640254, a next generation HIV-1 maturation inhibitor Wednesday 15:10-16:40 |
| III-04 Christer Rimmler Evaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models Thursday 09:55-11:20 |
| III-05 Viktor Rognĺs Bounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections Thursday 09:55-11:20 |
| III-06 Federico Romano Predictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine Thursday 09:55-11:20 |
| III-26 Tomás Sou Translational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin Thursday 09:55-11:20 |
| III-29 Gabriel Stillemans Simultaneous population pharmacokinetic modeling of darunavir and cobicistat in a cohort of HIV patients Thursday 09:55-11:20 |
| III-31 Herbert Struemper Population Pharmacokinetics of Belimumab Administered Intravenously in Children with Systemic Lupus Erythematosus Thursday 09:55-11:20 |
| III-34 Jesper Sundell Pharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV Thursday 09:55-11:20 |
| III-35 Budi Octasari Susanto Translational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development Thursday 09:55-11:20 |
| III-38 Lénaďg Tanneau Evaluating potential link between liver enzyme abnormalities and bedaquiline exposure in multi-drug resistant tuberculosis patients Thursday 09:55-11:20 |
| III-39 Joel Tarning Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria Thursday 09:55-11:20 |
| III-42 Anders Thorsted Model-based translation from piglets to healthy volunteers: Prediction of TNF-α and IL-6 time-courses in human endotoxin challenge studies Thursday 09:55-11:20 |
| III-43 Tjokosela Tikiso A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications. Thursday 09:55-11:20 |
| III-48 Sami Ullah Population pharmacokinetics of cefepime in critically ill patients with and without impaired renal function Thursday 09:55-11:20 |
| III-53 Stijn van Beek Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients Thursday 09:55-11:20 |
| III-58 Rob van Wijk Nanoscale pharmacokinetics and pharmacodynamics of isoniazid treatment of tuberculosis in zebrafish larvae Thursday 09:55-11:20 |
| III-61 Luka Verrest Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients Thursday 09:55-11:20 |
| III-65 Wenyi Wang Physiological Response to Endotoxin Infusion in the Piglet: Modelling of changes in hemodynamic outcomes Thursday 09:55-11:20 |
| III-67 Zhigang Wang A Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo Thursday 09:55-11:20 |
| III-71 Ferdinand Weinelt A joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients Thursday 09:55-11:20 |
| III-73 Quirin Werthner Network-based mathematical modelling of HPV transmission and cervical cancer in Germany. Thursday 09:55-11:20 |
| III-76 Justin Wilkins Population Pharmacokinetics analysis of M5717, a novel antimalarial agent Thursday 09:55-11:20 |
| III-80 Xia Li A Physiologically-Based Pharmacokinetic Model of Voriconazole Thursday 09:55-11:20 |
| III-81 Rujia Xie Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections Thursday 09:55-11:20 |
| III-84 Jinqiu Yin Pharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections Thursday 09:55-11:20 |
| III-88 Chenyan Zhao Colistin to overcome resistance to ciprofloxacin - Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model Thursday 09:55-11:20 |
| IV-12 Alan Faraj Drug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients Thursday 15:25-16:50 |
| IV-18 Jose Francis A semi-mechanistic model to characterise the influence of nevirapine- and lopinavir/ritonavir-based therapy on artemether and dihydroartemisinin exposure Thursday 15:25-16:50 |
| IV-20 Aline Fuchs Assessment of translation of PKPD relationship from animal to human for malaria compounds Thursday 15:25-16:50 |
| IV-25 Kamunkhwala Gausi Pharmacokinetics of isoniazid preventative therapy among HIV-infected pregnant women in high tuberculosis incidence settings Thursday 15:25-16:50 |
| IV-38 Jinju Guk Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers Thursday 15:25-16:50 |
| IV-41 Felix Hammann Population pharmacokinetics and generation of dosing nomograms of daptomycin at a Swiss university hospital Thursday 15:25-16:50 |
| IV-51 Richard Höglund Multidrug-resistant genotypes are associated with therapeutic failure of antimalarial therapy in Cambodia; a pharmacometric approach Thursday 15:25-16:50 |
| IV-58 Luis Ilia Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid Thursday 15:25-16:50 |
| IV-59 Khalid Iqbal Modelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin Thursday 15:25-16:50 |
| IV-61 Kris Oliver Jalusic Pharmacokinetics of vancomycin in the cerebrospinal fluid in critically ill patients Thursday 15:25-16:50 |
| IV-65 Mats Jirstrand A challenge model of TNFα turnover with LPS provocations and drug intervention Thursday 15:25-16:50 |
| IV-78 Aida Kawuma Dolutegravir pharmacokinetics in co-administration with rifampicin. Thursday 15:25-16:50 |
| IV-84 Dohyun Kim Optimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference Thursday 15:25-16:50 |
| IV-86 Franziska Isabelle Kluwe Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration Thursday 15:25-16:50 |
